Home LiteratureArticle Details
PMID: 10783010 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging.

Lipids ·Vol. 35 ·No. 3 ·2000-03-00 ·Pages 325-31

Williams JR

Abstract

With the passage of the U.S. Dietary Supplement Health and Education Act of 1994, dehydroepiandrosterone (DHEA, 5-androsten-3beta-ol-17-one) has become widely available, and a large and growing market has developed for this "fountain of youth." DHEA has been shown to have significant beneficial effects in animals, which may lead to clinical uses in man. Historically, the U.S. Food and Drug Administration removed DHEA from the over-the-counter market in 1985 because there was no support for the health claims that were made for this product. Almost all of the biological data was on animals and there was a lack of demonstrated efficacy in humans. Recently there have been a number of small clinical trials in humans but the results have not been as positive as in the animal tests. This review will be restricted to the effects of DHEA on carcinogenesis, obesity, the immune system, and aging. Four hypotheses have been proposed to explain the underlying biochemical mechanism(s) by which DHEA exerts its beneficial properties. The first is based on the inhibitory effect of DHEA on mammalian glucose-6-phosphate dehydrogenase. This mechanism can explain the antiinitiation and antipromotion steps in some cases of carcinogenesis. The second biochemical mechanism involves the induction of peroxisomes and peroxisome-associated enzymes. The third explanation is that DHEA works in a similar fashion to the known anticarcinogenic action of food restriction. An antiglucocorticoid mechanism has also been suggested. A hypothesis for the increase followed by the decrease in the levels of DHEA with age is proposed. A number of new synthetic DHEA analogs have been synthesized and tested. They offer the best hope for the development of a clinically useful drug based on the properties of DHEA.

MeSH Terms
Aging/drug effects Animals Dehydroepiandrosterone/pharmacology,therapeutic use Dehydroepiandrosterone Sulfate/pharmacology Glucosephosphate Dehydrogenase/antagonists & inhibitors Humans Immune System/drug effects Obesity/physiopathology,prevention & control
Chemicals
Dehydroepiandrosterone Dehydroepiandrosterone Sulfate Glucosephosphate Dehydrogenase
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Williams J R
Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, USA. [email protected]
References (50)
50 references, click to expand
  1. Lack of effect of dehydroepiandrosterone in obese men.
    Int J Obes. 1990 May;14(5):457-63 PMID: 2143499
  2. On the specificity of steroid interaction with mammary glucose 6-phosphate dehydrogenase.
    Biochemistry. 1970 May 26;9(11):2233-43 PMID: 4393184
  3. Therapeutic effects of dehydroepiandrosterone metabolites in diabetes mutant mice (C57BL/KsJ-db/db).
    Endocrinology. 1984 Jul;115(1):239-43 PMID: 6234160
  4. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
    J Clin Endocrinol Metab. 1996 May;81(5):1821-6 PMID: 8626841
  5. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer.
    Cancer Res. 1981 Sep;41(9 Pt 1):3360-3 PMID: 6455194
  6. INHIBITION OF MAMMALIAN GLUCOSE-6-PHOSPHATE DEHYDROGENASE BY STEROIDS.
    Proc Natl Acad Sci U S A. 1960 Apr;46(4):447-52 PMID: 16590626
  7. Serum gonadotropins and steroid hormones and the development of ovarian cancer.
    JAMA. 1995 Dec 27;274(24):1926-30 PMID: 8568986
  8. Protective effect of dehydroepiandrosterone against aflatoxin B1-and 7,12-dimethylbenz(a)anthracene-induced cytotoxicity and transformation in cultured cells.
    Cancer Res. 1975 Sep;35(9):2482-7 PMID: 125150
  9. Clastogenic action of tumor promoter phorbol-12-myristate-13 acetate in mixed human leukocyte cultures.
    Carcinogenesis. 1983 Oct;4(10):1313-6 PMID: 6616759
  10. Obesity, body fat distribution and sex hormones in men.
    Int J Obes Relat Metab Disord. 1993 Nov;17(11):643-9 PMID: 8281222
  11. Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone.
    Carcinogenesis. 1981;2(12):1335-7 PMID: 6459887
  12. Dehydroepiandrosterone. Metabolic effects.
    Acta Univ Carol Med Monogr. 1976;71:1-137, 146-71 PMID: 136178
  13. Sex-dependent, tissue-specific opposing effects of dehydroepiandrosterone on initiation and modulation stages of liver and lung carcinogenesis induced by dihydroxy-di-n-propylnitrosamine in F344 rats.
    Carcinogenesis. 1988 Aug;9(8):1507-9 PMID: 2969783
  14. Influence of dehydroepiandrosterone (DHEA) on cholesterol metabolism in rats.
    Pharmacol Res Commun. 1983 Oct;15(9):797-803 PMID: 6227919
  15. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy.
    J Clin Endocrinol Metab. 1994 Jun;78(6):1515-20 PMID: 8200956
  16. Biological actions of androgens.
    Endocr Rev. 1987 Feb;8(1):1-28 PMID: 3549275
  17. The effects of steroids on glucose-6-phosphate dehydrogenase.
    J Steroid Biochem. 1972 Apr;3(3):493-6 PMID: 4263745
  18. Induction of microsomal NADPH-cytochrome P-450 reductase and cytochrome P-450IVA1 (P-450LA omega) by dehydroepiandrosterone in rats: a possible peroxisomal proliferator.
    Cancer Res. 1989 May 1;49(9):2337-43 PMID: 2523237
  19. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones.
    J Endocrinol. 1996 Sep;150 Suppl:S155-64 PMID: 8943799
  20. Prevention of obesity in Avy/a mice by dehydroepiandrosterone.
    Lipids. 1977 May;12(5):409-13 PMID: 140989
  21. Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids.
    Carcinogenesis. 1981;2(8):717-21 PMID: 6456847
  22. The influence of dietary restriction on DNA repair in rodents: a preliminary study.
    Mech Ageing Dev. 1989 May;48(2):135-43 PMID: 2661931
  23. The effect of dietary restriction on myc protooncogene expression in mice: a preliminary study.
    Mech Ageing Dev. 1989 May;48(2):199-205 PMID: 2739468
  24. Dehydroepiandrosterone (DHEA) and 3 beta-methylandrost-5-en-17-one: inhibitors of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice.
    Carcinogenesis. 1984 Apr;5(4):463-6 PMID: 6231135
  25. Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women.
    Int J Obes Relat Metab Disord. 1996 Dec;20(12 ):1105-10 PMID: 8968856
  26. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood.
    J Clin Endocrinol Metab. 1984 Sep;59(3):551-5 PMID: 6235241
  27. Effect of dehydroepiandrosterone on growth in lean and obese Zucker rats.
    J Nutr. 1984 Jul;114(7):1242-51 PMID: 6234382
  28. Inhibition of proteinuria development in aging Sprague-Dawley rats and C57BL/6 mice by long-term treatment with dehydroepiandrosterone.
    J Gerontol. 1986 Jul;41(4):433-8 PMID: 2941474
  29. Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer.
    Gynecol Obstet Invest. 1987;23(4):271-4 PMID: 2956173
  30. Inhibition of 7,12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs.
    Carcinogenesis. 1989 Oct;10(10):1809-13 PMID: 2529051
  31. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.
    J Clin Endocrinol Metab. 1988 Jan;66(1):57-61 PMID: 2961787
  32. Relation between urinary androgen and corticoid excretion and subsequent breast cancer.
    Lancet. 1971 Aug 21;2(7721):395-8 PMID: 4105173
  33. Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone.
    Cancer Res. 1979 Mar;39(3):1129-32 PMID: 154968
  34. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.
    Cancer Res. 1992 Jan 1;52(1):1-4 PMID: 1530765
  35. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans.
    J Clin Endocrinol Metab. 1990 Nov;71(5):1259-64 PMID: 2146282
  36. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance.
    Metabolism. 1996 Aug;45(8):1011-5 PMID: 8769361
  37. Dehydroepiandrosterone: an anti-obesity and anti-carcinogenic agent.
    Nutr Cancer. 1981;3(1):46-53 PMID: 6213940
  38. Suppression of the first stage of phorbol 12-tetradecanoate 13-acetate-effected tumor promotion in mouse skin by nontoxic inhibition of DNA synthesis.
    Proc Natl Acad Sci U S A. 1984 Sep;81(18):5858-62 PMID: 6435122
  39. The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly.
    Mech Ageing Dev. 1998 May 15;102(2-3):299-306 PMID: 9720660
  40. Body mass and physical activity are important predictors of serum androgen concentrations in young healthy men.
    Epidemiology. 1995 Jul;6(4):432-5 PMID: 7548356
  41. Sex difference in the metabolism of dehydroisoandrosterone sulfate.
    J Clin Endocrinol Metab. 1980 Aug;51(2):334-6 PMID: 6447162
  42. Effect of short-term DHEA administration on liver metabolism of lean and obese rats.
    Am J Physiol. 1988 Jul;255(1 Pt 1):E1-8 PMID: 2968767
  43. Nutrition in relation to cancer.
    Adv Cancer Res. 1953;1:451-501 PMID: 13057710
  44. Inhibition by restricted-calorie diet of lymphoproliferative disease and renal damage in MRL/lpr mice.
    Proc Natl Acad Sci U S A. 1984 Oct;81(19):6144-8 PMID: 6592606
  45. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice.
    Cancer Res. 1985 Jan;45(1):164-6 PMID: 3155493
  46. Dehydroepiandrosterone and structural analogs: a new class of cancer chemopreventive agents.
    Adv Cancer Res. 1988;51:391-424 PMID: 2975913
  47. Reduced testosterone and adrenal C19 steroid levels in obese men.
    Metabolism. 1995 Apr;44(4):513-9 PMID: 7723675
  48. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies.
    Am J Obstet Gynecol. 1992 Apr;166(4):1163-8; discussion 1168-70 PMID: 1533090
  49. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice.
    Diabetes. 1984 Jan;33(1):26-32 PMID: 6228478
  50. Immunological properties of dehydroepiandrosterone, its conjugates, and metabolites.
    Ann N Y Acad Sci. 1999 Jun 22;876:91-101 PMID: 10415598
Article Info
Journal
Lipids
Abbr.
Lipids
ISSN
0024-4201
DOI
10.1007/s11745-000-0529-7
Email
[email protected]
Published
2000-03-00
Pages
325-31
Language
English
Region
United States
NLM ID
0060450
Subset
IM
External Links
PubMed source DOI: 10.1007/s11745-000-0529-7 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2